A monoclonal antibody specifically binding to human serum albumin and its application
Through the specific rabbit-derived monoclonal antibodies B6-4 and C2-3 and their chemiluminescence detection kits, the problems of low sensitivity and cumbersome operation of human serum albumin in the prior art are solved, and high sensitivity and rapid detection are achieved. Suitable for a wide range of testing.
Patent Information
- Application Number
- CN202310144238.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-02-21
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2043-02-21
AI Technical Summary
The prior art methods used for human serum albumin detection have low sensitivity, cumbersome operation, and a long detection time, making it difficult to meet the needs of high sensitivity and rapid detection.
A rabbit-derived monoclonal antibodies B6-4 and C2-3 specifically binding to human serum albumin were developed, and a chemiluminescence detection kit was designed based on this, using single-coupled magnetic particles and labeled acridinyl ester. Clonal antibodies are tested, combined with conventional magnetic particles coupled with monoclonal antibodies and coupling techniques of acridinium esters and monoclonal antibodies, to prepare a detection kit with high sensitivity and wide linear range.
It realizes high sensitivity and rapid detection of human serum albumin detection, is suitable for a wide range of detection, simplifies the operation process, and improves detection efficiency and accuracy.
Smart Images

Figure CN115894684B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and in particular relates to a monoclonal antibody specifically binding to human serum albumin and an application thereof. Background Art
[0002] Human serum albumin (HSA) is a serum albumin found in human blood. It is the most abundant protein in human plasma; it accounts for about half of serum protein. It is produced in the liver. It is easily soluble in water and is a monomer.
[0003] HSA is a highly water-soluble globular monomeric plasma protein with a relative molecular weight of 67KDa, consisting of 585 amino acid residues, a thiol group and 17 disulfide bonds. In body fluids, human serum albumin can transport fatty acids, bile pigments, amino acids, steroid hormones, metal ions and many therapeutic molecules, while maintaining normal blood osmotic pressure. Clinically, human serum albumin can be used to treat shock and burns, to supplement blood loss caused by surgery, accidents or massive bleeding, and can also be used as a plasma expander.
[0004] The normal range for human serum albumin in adults (>3 years) is 3.5–5.0 g / dL (35–50 g / L). For children under three years of age, the normal range is wider, 2.9–5.5 g / dL (29–55 g / L). Low albumin (hypoalbuminemia) may be caused by liver disease, nephrotic syndrome, burns, protein-losing enteropathy, malabsorption, malnutrition, late pregnancy, artifacts, genetic variations, and malignancy. High albumin (hyperalbuminemia) is almost always caused by dehydration. In some cases of retinol (vitamin A) deficiency, albumin levels may be elevated to high-normal values (e.g., 4.9 g / dL) because retinol causes cells to swell when they come into contact with water. (This is also why too much vitamin A is toxic.) This swelling may also occur during treatment with 13-cis retinoic acid (isotretinoin), a drug used to treat severe acne, among other conditions. In laboratory experiments, all-trans retinoic acid has been shown to downregulate albumin production in humans.
[0005] The detection of HSA is usually measured by recording the change in absorbance after binding with a dye (such as bromocresol green or bromocresol purple), which is a chemical reaction with low sensitivity. It is also detected by ELISA kit. Although it is an antigen-antibody specific reaction, the operation is cumbersome and time-consuming. Therefore, it is necessary to develop a kit with high sensitivity, reaction time period, and easy operation for the detection of HSA. Summary of the invention
[0006] In order to make up for the deficiencies of the prior art, the present invention aims to provide a monoclonal antibody that specifically binds to HSA and a detection kit for HSA established on the basis of the monoclonal antibody.
[0007] Therefore, on one hand, the present invention provides a monoclonal antibody that specifically binds to human serum albumin, wherein the monoclonal antibody is a rabbit monoclonal antibody, wherein the monoclonal antibodies are monoclonal antibody B6-4 and monoclonal antibody C2-3, and the sequences encoding the heavy chain variable region and light chain variable region of monoclonal antibody B6-4 are shown in SEQ ID NO.1 and SEQ ID NO.2, and the sequences encoding the heavy chain variable region and light chain variable region of monoclonal antibody C2-3 are shown in SEQ ID NO.3 and SEQID NO.4.
[0008] In another aspect, the present invention further provides a kit for detecting human serum albumin, the kit comprising an effective amount of the monoclonal antibody B6-4 and the monoclonal antibody C2-3 according to claim 1 and an effective amount of human serum albumin; and supporting reagents for detecting human serum albumin.
[0009] Preferably, the kit described in the present invention is a chemiluminescent detection kit, and the kit comprises a calibrator, a reagent R1, a reagent R2, a washing solution and an acridinium ester luminescent solution.
[0010] Preferably, the calibrator described in the present invention is human serum albumin of different concentrations, and the concentrations of human serum albumin of different concentrations are 3000ng / ml, 500ng / ml, 100ng / ml, 25ng / ml, 5ng / ml, 2.5ng / ml and 0ng / ml respectively.
[0011] Preferably, the reagent R1 described in the present invention is the monoclonal antibody B6-4 coupled to magnetic particles.
[0012] Preferably, the reagent R2 described in the present invention is a monoclonal antibody C2-3 labeled with acridinium ester.
[0013] Preferably, the washing solution of the present invention is PBST buffer.
[0014] In another aspect, the present invention also provides a use of the monoclonal antibody B6-4 and the monoclonal antibody C2-3 in the preparation of a human serum albumin detection reagent.
[0015] The human serum albumin antibody prepared by the present invention is a rabbit monoclonal antibody, which has the following advantages compared with the existing mouse monoclonal antibody:
[0016] 1) A wider antibody spectrum: After being injected with antigens, rabbits will produce a stronger immune response, and they will cause gene rearrangement due to somatic hypermutation, thereby producing VJ and VDJ antibody spectra, making their affinity more diverse. It is for this reason that rabbit antibodies can recognize more antigens that mouse monoclonal antibodies cannot recognize. 2) Simpler structure: Rabbit immunoglobulins do not contain IgD heavy chains, while serum contains abundant IG immunoglobulins and has no subclasses. Compared with mice, rabbit IgG tends to have fewer amino acids in the N-terminus and DE loop, and has additional disulfide chains in the heavy chain variable region, which also makes it more stable. It is precisely because of this structure that the molecules of rabbit monoclonal antibodies may become simpler and the experimental results are more stable. 3) Stronger affinity: We know that an important criterion for measuring the quality of a monoclonal antibody is its affinity. Rabbit monoclonal antibodies are at the picomolar level, which has a relatively stronger affinity. Because of their high affinity and high specificity, they have stronger experimental potential. 4) Humanization is simpler: Because rabbits have a large number of splenic lymphocytes, more biologically active RabMAbs can be produced through humanization, which helps us screen humanized cells with good performance and improve the efficiency of humanization.
[0017] In addition, the two monoclonal antibodies screened by the present invention have good sensitivity and specificity for HSA, and the HSA detection kit prepared on this basis also has good linearity and high sensitivity, and is suitable for large-scale detection of HSA.
[0018] Humanization of monoclonal antibodies based on the monoclonal antibodies of the present invention to make them have a wider application effect should also be within the scope of protection of the present invention. The rabbit monoclonal antibody preparation technology used in the present invention and the preparation method of the HSA detection kit (such as coupling of magnetic particles with monoclonal antibodies, coupling of acridinium esters with monoclonal antibodies) are all conventional methods, and the steps used are all conventionally used technologies disclosed in the prior art, so some SOPs are closer to the prior art. Therefore, the preparation method of the monoclonal antibody disclosed in the present invention and the preparation method of the kit of the present invention are not within the scope of protection of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 SDS-PAGE test results of three monoclonal antibodies.
[0020] Figure 2 Kit calibration results. DETAILED DESCRIPTION
[0021] The present invention is further described below in conjunction with specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art. Unless otherwise specified, the reagents and materials used in the following examples are commercially available.
[0022] Example 1: Preparation of HSA monoclonal antibody
[0023] Conventional rabbit monoclonal antibody preparation methods are generally divided into immunization-spleen cell separation-cell fusion-hybridoma cell screening-monoclonal antibody expression and purification. A brief description is as follows:
[0024] 1 Human serum albumin protein source: purchased from Sigma, product number A3782.
[0025] 2 Rabbit immunization
[0026] The above-mentioned HSA was used as an antigen and was immunized by subcutaneous injection on the back of the rabbit. 2 ml of blood was collected before immunization for later use. For the first immunization, 0.5 mg of the antigen was mixed with an equal amount of Freund's complete adjuvant and then immunized (0.2 ml / point*5 points). From the second to the fourth immunization, 0.5 mg of the antigen was mixed with an equal amount of Freund's incomplete adjuvant and then immunized (0.2 ml / point*5 points). The immunization interval was two weeks. The booster immunization was arranged 4 to 5 weeks after the fifth immunization. 0.5 mg of the antigen was mixed and injected intravenously (1 ml). The rabbit was killed 4 days after the injection and the spleen was collected for later use.
[0027] 3. Splenocyte Isolation
[0028] Remove fat and other tissues around the spleen in a culture dish; rinse with 1640 culture medium, place the spleen on a stainless steel sieve and squeeze through the sieve; suspend with 1640 culture medium and centrifuge at 1400rpm for 5min; discard the supernatant and repeat the washing once; resuspend the cells with 1640 culture medium and take a small amount of cell suspension for dilution; count the number of live cells with trypan blue staining; take a 2×10 8 The suspension of spleen lymphocytes is reserved.
[0029] The results showed that the survival rate of spleen cells measured by trypan blue staining counting method was 97.5%, indicating that the spleen cells had good activity and could continue cell fusion.
[0030] 4. Cell Fusion
[0031] Spleen cells were fused with rabbit bone marrow tumor cells 240E. 2×10 8 spleen lymphocytes and 1×10 8Mix 240E cells, add 1640 culture medium and centrifuge, discard the supernatant, and mix the two cells thoroughly into a paste. Preheat in a 37℃ water bath, and slowly add 50% polyethylene glycol solution preheated at 37℃. Then add 1640 culture medium preheated at 37℃ to dilute the polyethylene glycol and make it ineffective. Add 1640 culture medium and centrifuge, discard the supernatant, and suspend the cell pellet in HAT culture medium.
[0032] After testing, the cell fusion rate was 65% to 68%, indicating that the cell fusion was good and the screening of hybridoma cells could continue.
[0033] 5. Hybridoma Cell Screening
[0034] The fused cells were divided into 96-well cell culture plates with feeder cells using HAT as a selective culture medium and cultured in a 37°C, 5% CO2 incubator. After 3 weeks, the initial inspection was conducted, and the supernatant of the cell culture wells was taken and the positive clones were screened out by indirect ELISA. The hybridoma cells with positive initial inspection were transferred to 24-well cell culture plates. After one week, the hybridoma cells with strong affinity for secreting antibodies and good cell growth were screened out by indirect ELISA. One portion of the hybridoma cells was stored in liquid nitrogen, and one portion was cloned by limiting dilution. Generally, 5 polyclones were selected for monoclonalization. Each polyclone was divided into 3 96-well cell culture plates. After three weeks, the positive clones were screened out by indirect ELISA. More than 3 (about 10) positive wells were selected for each polyclone and transferred to 24-well cell culture plates. After one week, the hybridoma cells with strong affinity for secreting antibodies and good cell growth were screened out by indirect ELISA. One portion of the hybridoma cells was stored in liquid nitrogen, and one portion was used for expanded culture to produce rabbit monoclonal antibodies. Generally, two clones from different clones are selected for cloning again. After two clonings, a hybridoma cell line that stably secretes specific antibodies is finally obtained.
[0035] After cell fusion and three weeks, 24 positive clones were detected by indirect ELISA in 20 96-well plates (as shown in Table 1).
[0036] Table 1 Positive clones in indirect ELISA initial screening
[0037]
[0038] One week later, 24 positive wells in Table 1 were tested using indirect ELISA, and 16 were still positive (as shown in Table 2).
[0039] Table 2 Positive wells in 24-well plate after one week
[0040]
[0041] Comprehensive comparison The indirect ELISA titer and cell growth status were comprehensively compared, and the 5 polyclonal clones (A6, B4, B6, C2, and D5) in Table 2 were selected for subcloning, and each polyclonal clone was divided into 3 96-well cell culture plates. After subcloning, monoclonal transfection was performed, and the monoclonal rate and positive rate of each clone are shown in Table 3.
[0042] Table 3 Monoclonal rate and its positive rate
[0043] serial number A6 B4 B6 C2 D5 Monoclonal rate 18% 25% 23% 20% 21% Positive rate 90% 100% 100% 90% 90%
[0044] The positive wells of the subclones were transferred to 24-well plates for culture, and a total of 6 cloned cell lines were obtained. The indirect ELISA method was used for screening, and finally 4 highly specific hybridoma cells B6-1, B6-4, C2-3, and D5-3 were screened for freezing, of which B6-1 and B6-4 were screened from B4, C2-3 was screened from C2, and D5-3 was screened from D5. In order to use double antibody sandwich detection for HSA in the future, two hybridoma cells B6-4 and C2-3 were selected for subsequent production.
[0045] 6 Production of monoclonal antibodies
[0046] Monoclonal antibodies were produced using recombinant antibody technology. mRNA was isolated from B6-4 and C2-3 hybridoma cells, and the heavy and light chain genes of the hybridoma cell lines were cloned using RT-PCR (the heavy and light chain variable region sequences were sent to a sequencing company for sequencing at the same time). The genes were ligated with plasmids after enzyme digestion, clones were picked out by plating, plasmids were extracted by overnight culture of E. coli, and the heavy and light chain plasmids were paired and transfected into CHO cells for expression. Cells were collected aseptically and the culture supernatant was taken after centrifugation. This experiment was transfected twice. The first transfection used a small amount of transfection. The purpose was to screen out monoclonal cell lines with strong specificity and high affinity, and smoothly enter the second transfection for large-scale production. The screening method used indirect ELISA.
[0047] After sequencing, the sequences encoding the heavy chain variable regions and light chain variable regions of the B6-4 and C2-3 monoclonal antibodies are shown in SEQ ID NO.1 to SEQ ID NO.4.
[0048] After transfection on both sides, 50-100 ml of culture supernatant was obtained. After purification (using Protein A column purification), about 10 ml of purified monoclonal antibody was obtained. SDS-PAGE test (such as Figure 1 The purity of the monoclonal antibodies was above 90%. The concentration of the monoclonal antibodies B6-4 and C2-3 was 2.05 mg / ml and 2.25 mg / ml respectively. The monoclonal antibodies were stored at -80°C for later use.
[0049] Example 2: Indirect ELISA steps
[0050] 1 Coating: Use HSA protein to coat the ELISA plate. Use coating buffer (carbonate buffer) to dilute the HSA protein to 1 μg / ml, mix well and add to the ELISA plate, 0.1 ml per well, and coat overnight at 2-8°C.
[0051] 2 Blocking: Wash three times with PBST buffer, and then block with PBST buffer containing 5% skim milk, 0.2 ml per well, at 37 degrees for 2 hours;
[0052] 3 Add samples: After washing three times with PBST buffer, add samples (cell culture supernatant is generally not diluted or diluted 10 times, and the purified monoclonal antibody is diluted 10 times in series, and the diluent is PBST buffer), 0.1 ml per well, 37 degrees for 1 hour;
[0053] 4 Add secondary antibody: After washing three times with PBST buffer, add HRP-labeled goat anti-rabbit IgG secondary antibody (1:5000 dilution) to each well; incubate at 37 degrees for 0.5h;
[0054] 5 Color development: After washing three times with PBST buffer, add TMB color development solution, 0.1 ml per well, and incubate at 37 degrees for 10 minutes;
[0055] 6 Stop: Add stop solution (2M sulfuric acid), 0.05 ml per well, and detect OD450nm value immediately after termination; when P / N value (sample OD450nm value / blank control OD value) > 2.1 and OD450nm value > 0.1, it is judged as positive, otherwise it is negative.
[0056] Example 3: Preparation of HSA Detection Kit
[0057] 3.1 Preparation of Calibrators
[0058] The buffer for calibrator dilution was prepared according to Table 4, filtered through a 0.22 μm filter, and stored at 2-8°C for later use. HSA was then diluted in a gradient of 3000 ng / ml, 500 ng / ml, 100 ng / ml, 25 ng / ml, 5 ng / ml, 2.5 ng / ml, and 0 ng / ml.
[0059] Table 4 Calibrator Buffer
[0060] Components formula Hepes / mM 100 Proclin300 / % 0.1 sucrose / % 3 NaCl / % 1 Triton / % 0.5 pH 8.0
[0061] 3.2 Preparation of reagent R1: Take 5 mg of carboxylated magnetic particles (purchased from Shanghai Huizhi or thermo) in a 0.5 ml centrifuge tube, add 1 ml of 0.1 M MES buffer (pH 6.0), vortex to mix, place on a magnetic stand, let stand for 5 minutes to separate the magnetic particles from the liquid, discard the supernatant, wash 3 times, add 0.5 ml MES pH 6.0 buffer, vortex. Add 0.1 mg of monoclonal antibody B6-4 (a certain amount is taken according to the actual concentration), vortex, and incubate at room temperature for 20 minutes. Add 10 μl of coupling reagent EDC with a concentration of 10 mg / ml, vortex, and incubate at room temperature for 2 hours. After centrifugation, discard the supernatant, add 1 ml of PBST buffer, and wash 3 times. Add 1 ml of PBST buffer containing 1% BSA for blocking, and rotate and block at room temperature for 2 hours. After centrifugation, discard the supernatant, add 1 ml of PBST buffer, and wash 3 times. After centrifugation, discard the supernatant, add 1 ml of PBST buffer containing 1% BSA, and block at room temperature for 2 hours. Add 0.5 ml of PBST buffer containing 1% BSA to resuspend the magnetic particles and store at 2-8°C for later use. When used, dilute the monoclonal antibody B6-4 coupled to the magnetic particles 50 times with PBST buffer containing 1% BSA + 0.1% NaN3, at which time the concentration of the magnetic particles is 0.25 mg / ml, and store at 2-8°C for later use.
[0062] 3.3 Preparation of reagent R2: Weigh 1.6 mg of acridinium ester NSP-DMAE-NHS (purchased from McLean or other manufacturers), dissolve it in anhydrous DMSO, and prepare a 6.5 mM mother solution. In a light-proof environment, mix 5 μl of monoclonal antibody C2-3 (containing 5 μg, diluted with PBS according to the actual concentration) with 195 μl of acridinium ester mother solution, react at room temperature in the dark for 1 hour, add 100 μl of 10 g / L lysine, continue to react in the dark for 10 minutes, and terminate the labeling reaction. Inject the labeled solution into a Sephadex G-25 desalting column and wash with PBS. Detect protein with a chromatograph and detect protein concentration at 280 nm. To detect the labeled protein, take 10μl of acridinium labeled protein, place it in a black 96-well plate, inject 50μl~150μl of acridinium ester luminescent solution ((0.01~0.1M) NaOH+0.05% H2O2, prepared now for use) into each microwell, and detect immediately. If the luminescence is too strong, the labeled protein can be diluted several times to make it within the luminescence detection limit of the instrument; when the chromatograph shows an obvious protein peak, collect the effluent. Add 1% BSA+0.1% NaN3 to the effluent and store it in a dark place. A total of about 0.5ml of effluent is obtained. When using, dilute the acridinium ester labeled monoclonal antibody C2-3 400 times with PBST buffer containing 1% BSA+0.1% NaN3 and store it at 2~8℃ for later use.
[0063] 3.4 Kit detection steps
[0064] 1) 2μl sample + 50μl reagent R1 + 50μl reagent R2 + 98μl washing solution;
[0065] 2) Incubate with mixing at 37°C for 10 min (37°C 1000 rpm);
[0066] 3) Wash three times with washing solution, 500 μl each time;
[0067] 4) Add 200 μl of acridinium ester luminescent solution and immediately detect the RLU value using a chemiluminescence instrument.
[0068] The washing solution is PBST buffer, and the sample can be serum, whole blood, tissue fluid and cell culture fluid.
[0069] Example 4: Kit Performance Evaluation
[0070] 4.1 Kit linear range: The prepared kit was used to test the calibrator prepared in 3.1 according to the test steps in 3.4. The results showed (Table 5) that the kit had good linearity and uniformity in the concentration range of 2.5 ng / ml to 3000 ng / ml, indicating that the linear range of the kit was wide.
[0071] Table 5 Calibration results
[0072]
[0073] 3.2 Kit sensitivity: S0 was tested 20 times, and the average value of S0 plus 3 times the standard deviation was taken as the detection limit of this kit. After testing and calculation, the detection limit of this kit was 0.45ng / ml, indicating that the sensitivity of this kit is high.
[0074] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. A monoclonal antibody that specifically binds to human serum albumin, characterized in that: The monoclonal antibody is a rabbit monoclonal antibody, and the monoclonal antibody is monoclonal antibody B6-4 or monoclonal antibody C2-3, wherein the sequences encoding the heavy chain variable region and the light chain variable region of monoclonal antibody B6-4 are shown as SEQ ID NO.1 and SEQ ID NO.2, and the sequences encoding the heavy chain variable region and the light chain variable region of monoclonal antibody C2-3 are shown as SEQ ID NO.3 and SEQ ID NO.
4.
2. A kit for detecting human serum albumin, characterized in that: The kit comprises an effective amount of the monoclonal antibody B6-4 and the monoclonal antibody C2-3 described in claim 1 and an effective amount of human serum albumin; and a supporting reagent for detecting human serum albumin.
3. The kit according to claim 2, characterized in that The kit is a chemiluminescent detection kit, which includes a calibrator, a monoclonal antibody B6-4 coupled to magnetic particles, a monoclonal antibody C2-3 labeled with acridinium ester, a PBST buffer and an acridinium ester luminescent liquid; The calibrator is human serum albumin of different concentrations, and the concentrations of the human serum albumin of different concentrations are 3000ng / ml, 500ng / ml, 100ng / ml, 25ng / ml, 5ng / ml, 2.5ng / ml and 0ng / ml respectively.
4. Use of the monoclonal antibody B6-4 and the monoclonal antibody C2-3 as claimed in claim 1 in the preparation of a human serum albumin detection reagent.
